Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 6496 |
| PDBID: | 7R23 |
| Chains: | C_A |
| Organism: | Homo sapiens, Vicugna pacos |
| Method: | XRD |
| Resolution (Å): | 2.77 |
| Reference: | Not available or To be published |
| Antibody | |
| Antibody: | anti-Arc-1 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | human Arc CTD |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: C
Mutation: NULL
| >7R23_C|Chain C|Chain: C|Vicugna pacos (30538) GSEVQLVESGGGLVQAGGSLRLSCAASGRTSGALNVAWYRQATGKEREYVARLWWNDGTTYYSDSVKGRFTISSDNAKKIVYLQMNRLKPDDTAIYYCAVRTPSSQTLYWGQGTQVTVSS |
Antigen
Chain: A
Mutation: NULL
| >7R23_A|Chain A|ARC|Homo sapiens (9606) MHHHHHHLESTSLYKKAGSENLYFQSPGVDTQIFEDPREFLSHLEEYLRQVGGSEEYWLSQIQNHMNGPAKKWWEFKQGSVKNWVEFKKEFLQYSEGTLSREAIQRELDLPQKQGEPLDQFLWRKRDLYQTLYVDADEEEIIQYVVGTLQPKLKRFLRHPLPKTLEQLIQRGMEVQDDLEQ |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| C: SER2 GLU3 ARG29 LEU34 ASN35 TYR39 ARG47 TYR49 ARG52 TRP54 ASN56 ASP57 THR59 TYR61 ASP64 ARG101 THR102 PRO103 SER104 SER105 GLN106 THR107 LEU108 TRP110 A: LYS252 GLU255 PHE256 GLY277 ARG281 GLN285 TYR309 THR311 LEU312 TYR313 VAL314 ASP315 ASP317 GLU319 GLU320 GLN323 TYR324 VAL326 GLY327 LYS334 ARG335 ARG338 LEU341 LYS343 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
